Heartflow, which provides imaging and diagnostics software for evaluating coronary artery disease, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
Heartflow offers a non-invasive solution for diagnosing and managing coronary artery disease (CAD). As of March 31, 2025, the Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone. The novel platform leverages AI and advanced computational fluid dynamics to create a personalized 3D model of a patient's heart and deliver actionable insights on blood flow, stenosis, plaque volume, and plaque composition.
The Mountain View, CA-based company was founded in 2007 and booked $136 million in revenue for the 12 months ended March 31, 2025. It plans to list on the Nasdaq under the symbol HTFL. Heartflow filed confidentially on February 6, 2025. J.P. Morgan, Morgan Stanley, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
